Cargando…

Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments.

Detalles Bibliográficos
Autores principales: Osei-Bordom, Daniel C., Sachdeva, Gagandeep, Christou, Niki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795626/
https://www.ncbi.nlm.nih.gov/pubmed/35096878
http://dx.doi.org/10.3389/fmed.2021.788869
_version_ 1784641111553212416
author Osei-Bordom, Daniel C.
Sachdeva, Gagandeep
Christou, Niki
author_facet Osei-Bordom, Daniel C.
Sachdeva, Gagandeep
Christou, Niki
author_sort Osei-Bordom, Daniel C.
collection PubMed
description Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments.
format Online
Article
Text
id pubmed-8795626
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87956262022-01-29 Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma Osei-Bordom, Daniel C. Sachdeva, Gagandeep Christou, Niki Front Med (Lausanne) Medicine Pancreatic ductal adenocarcinomas (PDAC) represent one of the deadliest cancers worldwide. Survival is still low due to diagnosis at an advanced stage and resistance to treatment. Herein, we review the main types of liquid biopsy able to help in both prognosis and adaptation of treatments. Frontiers Media S.A. 2022-01-14 /pmc/articles/PMC8795626/ /pubmed/35096878 http://dx.doi.org/10.3389/fmed.2021.788869 Text en Copyright © 2022 Osei-Bordom, Sachdeva and Christou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Osei-Bordom, Daniel C.
Sachdeva, Gagandeep
Christou, Niki
Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title_full Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title_fullStr Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title_full_unstemmed Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title_short Liquid Biopsy as a Prognostic and Theranostic Tool for the Management of Pancreatic Ductal Adenocarcinoma
title_sort liquid biopsy as a prognostic and theranostic tool for the management of pancreatic ductal adenocarcinoma
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795626/
https://www.ncbi.nlm.nih.gov/pubmed/35096878
http://dx.doi.org/10.3389/fmed.2021.788869
work_keys_str_mv AT oseibordomdanielc liquidbiopsyasaprognosticandtheranostictoolforthemanagementofpancreaticductaladenocarcinoma
AT sachdevagagandeep liquidbiopsyasaprognosticandtheranostictoolforthemanagementofpancreaticductaladenocarcinoma
AT christouniki liquidbiopsyasaprognosticandtheranostictoolforthemanagementofpancreaticductaladenocarcinoma